Answers are grounded in this paper and cite their sources.
Cohort study reveals elevated neutrophil-to-lymphocyte ratio predicts worse survival across six solid tumors, highlighting its utility for individualized prognostic risk stratification.
BACKGROUND/AIM: Systemic inflammation is increasingly recognized as a key hallmark of cancer progression and an important determinant of patient outcomes, reflecting the balance between tumor-promoting inflammatory activity and anti-tumor immune competence. Using routinely available peripheral blood counts, we evaluated the prognostic value of the neutrophil-to-lymphocyte ratio (NLR) across several common malignancies and developed a pragmatic model for overall survival risk estimation. PATIENTS AND METHODS: From the INSCOC registry, 14,425 patients with lung, gastric, colorectal, liver, brain, or breast cancer were included and randomly split (10,098/4,327) into training and validation sets. Six inflammation-based indices from neutrophil, lymphocyte, and platelet counts were compared for overall survival (OS) using Harrell's C-index and time-dependent receiver operating characteristic (ROC) curves. Associations between NLR and OS were tested by Kaplan-Meier curves, restricted cubic splines, and multivariable Cox models adjusted for demographic, clinical, and treatment factors. A nomogram incorporating NLR and selected routinely available clinical variables was developed and internally evaluated by calibration analysis. The risk increased progressively with higher NLR and remained significant after multivariable adjustment. Associations were broadly consistent across age, sex, comorbidity, and treatment subgroups. The NLR-based nomogram showed generally acceptable calibration for estimating 1-, 3-, and 5-year survival. CONCLUSION: Elevated NLR independently signals worse survival across several major solid tumors and showed higher prognostic discrimination than other evaluated inflammation-derived indices. The proposed nomogram may provide a simple, clinically applicable tool to support individualized risk stratification using routinely available data.
No takes yet. Share an insight, caveat, or question.
Cai et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: